Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Overview of attention for article published in Clinical Cancer Research, July 2025

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

bluesky: 1 Bluesky user

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 9,455 followers.

Read the October Editors' Picks: Nelitolimod–Pembrolizumab Anti–PD-1 Treatment-Na¨ ıve Melanoma https://t.co/uQ6ACbVNod Milademetan in MDM2-Amplified, TP53-WT Solid Tumors https://t.co/KhDZEFRkbN https://t.co/aGNF5n9rNM

RT @DermOncPubMed: #Clin_Cancer_Res @CCR_AACR Phase 2 trial (n=86). Intratumoral nelitolimod (2 mg/8 mg) + pembrolizumab in anti-PD-1-naive…

#Clin_Cancer_Res @CCR_AACR Phase 2 trial (n=86). Intratumoral nelitolimod (2 mg/8 mg) + pembrolizumab in anti-PD-1-naive advanced melanoma showed ORR 76%/49% & 18-mo PFS 62%/40%. PMID:40711475 https://t.co/yTfr46PzM8

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.